secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001193125-23-180591
Event type: regulatory
Sentiment:  neutral
Materiality: 0.15
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology self-reports Nasdaq rule violation; remediated via share repurchase
--------------------------------------------------------------------------------

- Issued 6,110,000 shares at $6.55 in May 2023 offering, inadvertently exceeding 20% threshold of pre-transaction voting shares.
- Repurchased 97,500 shares from an investor to remediate the excess issuance and self-reported to Nasdaq.
- Nasdaq determined compliance with Listing Rule 5635(d) is regained; matter closed with no effect on listing of IKNA common stock.
- Company remains listed on The Nasdaq Global Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312523180591/0001193125-23-180591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312523180591/d466366d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-180591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer